Heron Therapeutics (HRTX) Competitors $1.63 +0.06 (+3.82%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends HRTX vs. OCS, NUVB, AVXL, CVAC, ABCL, AVBP, COGT, PAHC, RLAY, and CDMOShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Oculis (OCS), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), CureVac (CVAC), AbCellera Biologics (ABCL), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Relay Therapeutics (RLAY), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Oculis Nuvation Bio Anavex Life Sciences CureVac AbCellera Biologics ArriVent BioPharma Cogent Biosciences Phibro Animal Health Relay Therapeutics Avid Bioservices Heron Therapeutics (NASDAQ:HRTX) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations. Does the MarketBeat Community believe in HRTX or OCS? Heron Therapeutics received 636 more outperform votes than Oculis when rated by MarketBeat users. However, 90.32% of users gave Oculis an outperform vote while only 68.88% of users gave Heron Therapeutics an outperform vote. CompanyUnderperformOutperformHeron TherapeuticsOutperform Votes66468.88% Underperform Votes30031.12% OculisOutperform Votes2890.32% Underperform Votes39.68% Do insiders & institutionals believe in HRTX or OCS? 80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 5.8% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer HRTX or OCS? In the previous week, Oculis had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Oculis and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.85 beat Oculis' score of 0.11 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, HRTX or OCS? Oculis has lower revenue, but higher earnings than Heron Therapeutics. Oculis is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeron Therapeutics$127.04M1.95-$110.56M-$0.18-9.06Oculis$980K939.77-$98.92M-$1.93-11.78 Do analysts rate HRTX or OCS? Heron Therapeutics currently has a consensus target price of $5.67, suggesting a potential upside of 247.65%. Oculis has a consensus target price of $28.80, suggesting a potential upside of 26.65%. Given Heron Therapeutics' higher possible upside, research analysts clearly believe Heron Therapeutics is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is HRTX or OCS more profitable? Heron Therapeutics has a net margin of -20.31% compared to Oculis' net margin of -8,043.28%. Heron Therapeutics' return on equity of 0.00% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Heron Therapeutics-20.31% N/A -12.72% Oculis -8,043.28%-71.31%-56.85% Which has more volatility & risk, HRTX or OCS? Heron Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Oculis has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500. SummaryHeron Therapeutics beats Oculis on 12 of the 17 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$235.75M$6.34B$5.21B$8.93BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-9.069.8989.8017.35Price / Sales1.95315.771,248.2377.32Price / CashN/A61.4443.8235.97Price / Book-7.096.055.324.79Net Income-$110.56M$154.90M$122.69M$225.00M7 Day Performance5.16%-1.70%-0.17%1.52%1 Month Performance6.54%1.93%3.49%4.88%1 Year Performance-22.01%3.14%25.79%20.12% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics3.9335 of 5 stars$1.63+3.8%$5.67+247.6%-22.0%$235.75M$127.04M-9.06300News CoveragePositive NewsOCSOculis2.4546 of 5 stars$22.07+4.3%$28.80+30.5%+107.9%$893.92M$980,000.00-11.442Short Interest ↑Gap UpNUVBNuvation Bio2.393 of 5 stars$2.65-4.7%$7.40+179.2%+67.0%$891.90M$2.16M-1.2260Short Interest ↑Gap DownAVXLAnavex Life Sciences3.6923 of 5 stars$10.51-6.4%$44.00+318.6%+53.2%$891.42MN/A-21.0240Positive NewsCVACCureVac3.84 of 5 stars$3.96-5.9%$10.00+152.5%+12.6%$886.57M$543.28M7.20880ABCLAbCellera Biologics2.7428 of 5 stars$2.93+0.3%$8.33+184.4%-42.8%$865.42M$32.96M-4.80500Gap UpAVBPArriVent BioPharma1.1749 of 5 stars$24.80-0.3%$36.80+48.4%N/A$835.69MN/A0.0040Short Interest ↑News CoverageCOGTCogent Biosciences1.5242 of 5 stars$7.51-4.2%$14.83+97.5%+74.2%$829.57MN/A-3.0380Analyst ForecastShort Interest ↑News CoveragePAHCPhibro Animal Health4.2296 of 5 stars$20.13+0.4%$20.50+1.8%+83.8%$815.33M$1.05B46.821,860Analyst RevisionRLAYRelay Therapeutics2.4442 of 5 stars$4.76+7.0%$20.50+330.7%-56.7%$796.74M$10.01M-1.82330Analyst ForecastShort Interest ↑News CoverageCDMOAvid Bioservices2.3784 of 5 stars$12.42+0.1%$12.25-1.4%+102.8%$794.42M$150.45M-5.20320 Related Companies and Tools Related Companies Oculis Competitors Nuvation Bio Competitors Anavex Life Sciences Competitors CureVac Competitors AbCellera Biologics Competitors ArriVent BioPharma Competitors Cogent Biosciences Competitors Phibro Animal Health Competitors Relay Therapeutics Competitors Avid Bioservices Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HRTX) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
